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Abstract 
In recent years, the poorly remarkable goals achieved in terms of patients’ important 
outcomes for ovarian cancer have fueled our interest towards the study of its 
metabolic roots. Within this research pipeline, we assessed the association between 
the expression of the glucose transporter GLUT1, as expressed at the tumor tissue 
level, and circulating pre-surgical levels of fasting glucose in a case series including 
data from 40 patients with high FIGO stage serous ovarian cancer. Patients who 
provided data to the current analysis were randomly selected from a larger cohort. To 
our purposes, the procedures related to serum and tissue collection, storage and 
biomarker assessment were highly standardized and centralized at the institutional 
laboratories. The GLUT1 antibody SPM498 SPRING (REF. E13810) was used at a 
1:500 dilution in 2 μm slides. Staining for GLUT1 was observed at the cell 
membrane level in all the cases assessed, but strong staining was described in 29 
(72.5) of them. The agreement between the two independent reviewers was 100%. 
Strong GLUT1 staining was inversely associated with the circulating levels of fasting 
glucose, with a particularly striking difference in the distribution for patients in the 
lowest fasting glucose tertile (p=0.044). These results support the biological 
plausibility of the association of interest. If confirmed in larger studies, our findings 
may help clarify the potentials of biomarkers related to energy metabolism in terms 
of prognosis definition, treatment assignment and outcome interpretation for patients 
with high FIGO stage serous ovarian cancer. This article is protected by copyright. 
All rights reserved 
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Introduction 
 
In Western countries, ovarian cancer (OvCa) is sadly renown because of its highly 
lethal potentials, which have been barely contained over the past decades (Ferlay et 
al. 2015). The vast majority of OvCa patients are diagnosed with serous, high grade, 
high stage epithelial carcinoma. As such, these patients are managed throughout a 
combined approach including surgery and platinum-based regimens. Recent 
achievements of significant relevance include, though are not limited to, the addition 
of bevacizumab to the paclitaxel plus carboplatin regimen concurrently and then 
additionally as single-agent consolidation and maintenance therapy (Burger et al. 
2011, Stuart et al. 2011), along with the approval of olaparib in BRCA defective 
OvCa patients (Kim et al. 2015, Liu & Matulonis 2016). However, a dramatic 
amelioration of patient important outcomes is tightly linked to the understanding of 
determinants and mechanisms underlying OvCa onset and progression. 
 
In a recently published work from our research group with a focus on the potential 
role of metabolic and anthropometrics determinants on ovarian carcinogenesis, we 
observed an inverse association between fasting glucose and FIGO stage at diagnosis 
in 147 non diabetic OvCa patients treated with platinum based regimens and/or 
surgery at our Institute. This association was confirmed in subgroup analysis 
including body mass index (BMI) data (Vici et al. 2016). On an completely 
speculative ground, we hypothesized that the fluctuation of circulating glucose levels 
may be related to differences in the expression of the transporter protein 1 (GLUT1) 
in OvCa patients with advanced FIGO (International Federation of Gynecolists and 
Obstetrics) stage at diagnosis. Lower levels of fasting glucose and higher expression 
rates of GLUT 1 in ovarian cancer tissues may be indicative at the systemic and local 
level of a sort of adaption of the host organism to the enhanced energy necessities 
dictated by the ongoing carcinogenetic process. 
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To test our hypothesis, we have now assessed GLUT1 expression at the OvCa tissue 
levels in a sub-cohort of randomly selected patients from a group of patients with 
clinically annotated tissue samples and for whom centrally measured fasting glucose 
levels were available.  
 
Patients and Methods 
 
We analyzed data related to a subgroup of 40 OvCa patients diagnosed and treated at 
the Regina Elena National Cancer Institute. The list of patients whose tissues were 
immonostained was randomly selected from an initial pool of 147 women who 
represented the overall cohort whose data were analyzed in our prior study.  
Archival, routinely processed, formalin fixed, paraffin-embedded (FFPP) surgical 
pathology specimens from 40 patients diagnosed with serous cystadenocarcinomas 
were assessed. GLUT1 transporter was detected by immunohistochemistry using the 
labeled streptavidinbiotin procedure.10–12 Sections were deparaffinized in xylene, 
and cells were rehydrated in decreasing ethanol solution. Endogenous peroxidase was 
neutralized using 6% hydrogen peroxide for 3 min. The 2 μm slides were exposed to 
heat-induced antigen retrieval using a steamer, to be further washed and incubated for 
30 min at 22°C with a GLUT1. Tissues were counterstained with hematoxylin. All 
slides were examined by light microscopy. Two pathologists independently reviewed 
the slides and the involvement of a third reviewer was foreseen in case of 
disagreement. The GLUT1 antibody (Ab) SPM498 SPRING (REF. E13810) was 
used at a 1:500 diluition. To the purposes of our research, the control case was 
represented by tissue specimen from a cystoadenoma case. All sections were 
analyzed. Intensity of staining was quantified using a 0 to 3 score with regards to the 
percentage of position marking at high magnification: no marking (0); less than 20% 
(1+); 20–50% (2+); and more than 50% (3+).  
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Descriptive statistics were performed for all the variables of interest, including 
demographics, reproductive history, life-style habits, anthropometrics, disease grade 
and stage and modalities of surgical managements. Means and standard deviations 
(SD) were used to report on continuous variables, while categorical data were 
rendered by crude numbers and percentages. Categories of immunostaining were 
compared across strata of fasting glucose levels using the Chi square test. The cut off 
values for tertile definition were computed at the study population level. Statistical 
analyses were performed by SPSS software, version 21. 
 
Results 
The present analysis includes data from 40 OvCa patients diagnosed and treated at 
the Regina Elena Cancer Institute. This study population represents a randomly 
selected subgroup of patients from a wider cohort including 147 OvCa patients. The 
characteristics of the larger cohort were diffusely reported elsewhere (6). We now 
report on the subsets of patients, whose main features are summarized in table 1. 
In our case series, mean age at diagnosis was 54.9 years (10.5), most of our patients 
were postmenopausal (27, 67.5%), and all but 1 were no smokers (39, 97.5%). 
Median body mass index (BMI) was 24.6 (4.3). As commonly observed, the vast 
majority of our patients exhibited a high grade (33, 82.5%), high stage (30, 75%) 
serous cystoadenocarcinoma at diagnosis. In a limited number of these women, one 
or more degrees had been diagnosed with malignancies over the previous years (7, 
17.5). However, none of the familial medical histories fuelled doubts concerning 
BRCA defective diseases, neither these patients were genetically assessed. The 
performance status (PS) was on average acceptable. For the vast majority of these 
women, laparotomy represented the surgical treatment of choice (26, 65%).  
 
Staining for GLUT1 was observed at the cell membrane level, in yellowish brown 
(figure 1a and 1b). Positive staining was observed in all the cancer cases assessed, 
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with strong staining being described in 29 (72.5) of them. The agreement between the 
two independent reviewers was 100%.  
 
The association between circulating levels of fasting glucose and intensity of staining 
for GLUT1 in the 40 OvCa patients of interest is shown in table 2. Strong GLUT1 
staining was inversely associated with the circulating levels of fasting glucose across 
glucose tertiles, whose cut off values were defined at this population level (p=0.044). 
The difference in distribution between weak and strong staining appeared particularly 
evident for patients in the lowest fasting glucose tertile (N:13), wherein the ratio 
between week and strong staining was 1:12.  
 
Discussion 
 
We herein report on the results from a restricted, though well characterized, cohort of 
patients with high stage, serous OvCa who were diagnosed and treated at the Regina 
Elena National Cancer Institute. This is an ancillary study from a larger observational 
study of 147 OvCa patients. In this latter cohort we first observed an inverse 
association between high FIGO stage at diagnosis and circulating level of fasting 
glucose. Our interest towards the characterization of factors involved in OvCa onset 
and progression, jointly with the renown prognostic relevance of stage at diagnosis in 
the disease of interest, prompted us to verify the biologic plausibility of the above 
reported association. We thus randomly extracted a subset of 40 OvCa patients for 
whom clinically annotated tissue samples were still available and assessed them by 
immunohistochemistry for GLUT1 expression. The results observed were in key with 
the hypothesis stated in our previous work (Vici et al. 2016). Indeed, we were able to 
confirm a significantly stronger GLUT1 staining in cases whose fasting glucose 
values fell in the lowest tertile of the distribution in this study population.  
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The role played by GLUT1 expression in carcinogenesis has been repeatedly 
investigated for ovarian and other cancers. In a quite recent study, Cai et al have 
observed loss of GLUT1 expression in tissue samples from non oncologic patients, 
while in the benign, borderline and malignant tumors the intensity of staining 
reported in percentages were 66, 100 and 100, respectively (Cai et al. 2014). Within 
this same study, the authors also found evidence of a direct association between 
GLUT1 expression and stage at diagnosis, which is consistent with the findings from 
prior studies (Kalir et al. 2002, Tsukioka et al. 2007). This is also confirmed by our 
results from the main study (Vici et al. 2016) and from the current analysis, when 
addressing distribution of cancer stage at diagnosis across tertiles of fasting glucose 
(supplementary table 1). Indeed, 12 out of the 13 patients from the subgroup of 
patients with the lowest fasting glucose levels were diagnosed with high FIGO stage 
tumors. The remarkable representation of high FIGO stage OvCa cases among those 
with intense staining for GLUT1 is also in key with a lower chance for optimal 
cytoreduction, as reported by Seman and co-authors based on data from 213 patients 
with OvCa assessed by immunohistochemistry for GLUT-1, Ki-67, and vascular 
endothelial growth factor (Semaan et al. 2011). More in general, results from several 
studies are consistent in supporting the negative prognostic and, in some cases, 
predictive role of GLUT1 expression in several pathologic conditions, including 
esophageal cancer, colorectal cancer and renal cell cancer (Egawa-Takata et al. 2010, 
Fonteyne et al. 2009, Lamkin et al. 2009, Martins et al. 2016, Sawayama et al. 2014, 
Shao et al. 2007, Tohma et al. 2005, Tsukioka et al. 2007, Wang et al. 2016). 
 
Results from the present work may be interpreted in light of the key role played by 
GLUT1 in the adaption of the host organisms to the compelling changes required by 
carcinogenesis in terms of energy and metabolic consumption. Indeed, as the most 
important carrier of mammalian glucose transport across cell membranes into the 
cell, GLUT1 involvement has been ascertained not only under physiologic 
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circumstances, but also in pathologic conditions spanning from inflammation to 
cancer (He et al. 2007). 
Our work is entirely based on the association between the results obtained from the 
immunostaining and the previously available data on fasting glucose levels. In the 
present manuscript, no referral is made to patients’ important outcomes. The process 
of data collection for treatment outcomes including platinum sensitivity/resistance, 
progression free survival and overall survival, was started long ago and has now 
covered approximately half of the original cohort. The current study, whose limited 
size was dictated by its spontaneous nature, is statistically underpowered to address 
research questions pertinent to treatment outcomes. However, and in the full respect 
of the previously cited limitations, survival data seemed to provide some evidence of 
better outcomes in the subgroup of patients placed within the highest tertile of fasting 
glucose, which is also characterized by the weakest staining (supplementary figure 1). 
As expected, such evidence is not statistically relevant (p=0.57). In addition, the 
association addressed seems not linear across the fasting glucose tertiles, which may 
indicate the existence of a threshold to be reached for highlighting the effect of 
interest. This finding is somewhat consistent with our prior work on the predictive 
role of fasting glucose in breast cancer from our research group (Barba et al. 2012). 
 
Novelty and feasibility represent the main strengths of this work. Although several 
previous studies have assessed the role of GLUT 1 in ovarian carcinogenesis, with 
quite consistent results, we report on a first time finding concerning the association 
between a biomarker of glucose metabolism expressed at the ovarian tissue level, i.e., 
GLUT1, and an easily and cheaply available biomarker of energy metabolism which 
reflects the overall systemic asset of the host organism. As a matter of fact, fasting 
glucose measurement is ordinarily performed in view of our patients’ surgical and/or 
laparoscopic management, and as such, is easily amenable to be systematically 
recorded not only for clinical but also for research purposes. At the same time, 
GLUT1 assessment at the ovarian cancer tissue level is a highly standardizable 
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process, with overall affordable costs. In addition, from a methodological standpoint, 
the centralization of any procedure related to the collection, short and long term 
storage and assessment of both sera and tissue samples adds substantial value to our 
work and increase our confidence in the results obtained. 
 
This study also has some weaknesses. The number of samples assessed is limited, 
although not excessively, particularly in light of relative low frequency of the disease 
of interest (Ovarian cancer statistics | World Cancer Research Fund International). 
As previously mentioned, the complete lack of outcome data will be soon 
counterbalanced by the results of the outcome analysis on the original cohort. In 
addition, the exclusive use of an immunohistochemical assessment in the approach to 
the association of interest may need integrations from different assessment levels. 
The impact of GLUT expression and circulating levels of fasting glucose in this 
patient subset and in the larger series is current under investigation in a study focused 
on the role microRNA in outcome prediction and interpretation in high grade serum 
ovarian cancer patients treated with platinum based regimens.  
 
In conclusions, throughout the conduct of a study including data from an 
homogeneous case series of 40 non diabetic patients diagnosed with high FIGO stage 
OvCa at one single Institution, we first observed and reported on the existence of a 
significant inverse association between immonostaining of OvCa tissues for the 
glucose transporter GLUT1 and circulating levels of fasting glucose assessed at the 
Institutional laboratories. Although well aware of the relatively restricted size of the 
study population, the highly standardized procedures applied to this single institution  
series make us confident in the quality of our data and encourage further stepping 
along our research pipeline on the metabolic roots of OvCa. Pending confirmation 
from further and more adequately sized studies, our results may provide further 
support to the use of energy biomarkers in better defining patient prognosis and 
informing therapeutic decisions and related outcome interpretation.  
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Table 1: Main baseline patient characteristics (N:40). 
 
Characteristics     
1Age at cancer diagnosis                   (mean, ±SD)  54.9 ±10.5 
     
Menopausal Status                                       (N, %) Premenopausal 13 32.5 
 Postmenopausal 27 67.5 
     
Smoking status                                             (N, %) Yes 1 2.5 
 No 39 97.5 
    
2Height at Baseline                          (mean, ±SD)  159.2 ±5.5 
    
3 Weight at Baseline                      (mean, ±SD)  62.3 ±11.4 
    
4BMI at Baseline                                (mean, ±SD)  24.6 ±4.3 
    
Grade G1 1 2.5 
 G2 6 15.0 
 G3 33 82.5 
    
5FIGO Stage at Cancer Diagnosis           (N, %) I 5 12.5 
 II 5 12.5 
 III 29 72.5 
 IV 1 2.5 
    
6Fasting Glucose at Baseline #               (mean, ±SD)  95.7 ±20.1 
    
Familiarity Yes 7 17.5 
 No 33 82.5 
    
7PS 0 36 90.0 
 1 4 10.0 
    
Type of surgery 8LPS 14 35.0 
 9LPT 26 65.0 
1  in years, 2 in centimeters, 3 in kilograms (Kg), 4 Body Mass Index in m2/Kg, 5 International Federation of Gynecology 
and Obstetrics; 6 milligrams/dl; 7 Performance Status; 8 Laparoscopy; 9 Laparotomy  
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Table 2: Associations between circulating levels of tertiles of fasting glucose and 
intensity of staining for transporter protein 1 (GLUT1) in ovarian cancer patients 
(N:40). 
 
1 Milligrams/dl; 2 Intensity of staining for GLUT was quantified using a 0 to 3 score, as it follows: 
no marking (0); less than 20% (1+); 20–50% (2+); and more than 50% (3+). 
 
 
 
 
 
 
 
  1Fasting glucose  
 
 
  ≤86 86-94 >94 Chi2 
 
  N (%) N (%) N (%) p-value 
 
2GLUT1 SI  
 
 
0-1 
 
1 (9.1) 
 
3 (27.3) 
 
7 (63.6) 
 
0.044 
 2-3 12 (41.4) 10 (34.5) 7 (24.1)  
      
